Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights.
Dr. Oliver Medvedik, LEAF vice president and Director of the Maurice Kanbar Center for Biomedical Engineering at the Cooper Union, chaired a panel with a focus on starting up biotech companies and dealing with the challenges inherent to launching a company in this industry.
In this panel, Dr. Oliver Medvedik, Dr. Michael West of AgeX Therapeutics, Kelsey Moody of Ichor Therapeutics, Stephen Hilbert of Oisin Biotechnologies, Dr. Sudhir Paul of Covalent Bioscience, Bobby Brooke of Intervene Immune, and Reason of Repair Biotechnologies/Fight Aging! discuss their experiences in the creation of successful startup companies in the aging research sector.
Here, they touch upon the huge gap between the lab and the commercial world and the way that promising ideas in the lab can often fail early and vanish into the valley of death, discuss intellectual property (IP) and its place in developing biotechnology, and discuss other pitfalls of creating a new rejuvenation biotech company.
We were aiming for our conference to offer the latest aging research while providing solid advice, guidance, and insights from the worlds of biotech startups and investment. We are confident that we achieved this and hope that you will enjoy this informative panel.